Autoimmune Polyglandular Syndrome Type 1
Rare autoimmune disorder causing multiple endocrine failures, chronic candidiasis, and ectodermal dystrophy.
Authoritative facts from DermNet New Zealand – all about autoimmune polyglandular syndrome type 1 (APS-1), also known as autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED).
What is autoimmune polyglandular syndrome type 1?
Autoimmune polyglandular syndrome type 1 (APS-1) is a rare autosomal recessive genetic disorder caused by mutations in the autoimmune regulator (AIRE) gene on chromosome 21q22.3. This gene plays a critical role in promoting the expression of tissue-specific antigens in the thymus, enabling negative selection of autoreactive T cells and establishing central immune tolerance. Defects in AIRE lead to immune dysregulation, resulting in chronic mucocutaneous candidiasis and a spectrum of autoimmune endocrinopathies and ectodermal manifestations.
APS-1 typically presents in childhood with a classic triad: chronic mucocutaneous candidiasis (CMC), hypoparathyroidism, and adrenal insufficiency (Addison disease). However, over 20 other autoimmune conditions may develop sequentially, affecting multiple organ systems. The disorder affects approximately 1 in 100,000–200,000 individuals worldwide, with higher prevalence in certain populations such as Finns, Sardinians, and Iranian Jews. HLA-DR/DQ alleles influence the specific autoimmune components that manifest in affected individuals.
Who gets autoimmune polyglandular syndrome type 1 (epidemiology)?
APS-1 is exceptionally rare, with an estimated incidence of 1:100,000 to 1:200,000. It exhibits a distinct geographical distribution:
- Finland: Founder mutation (R257X in AIRE), prevalence ~1:25,000.
- Sardinia: High frequency due to founder effect.
- Iranian Jews: Specific mutations reported.
- Other clusters in Norway, Ireland, and Eastern Europe.
The disorder affects both sexes equally and typically manifests in early childhood, with candidiasis often appearing first (before age 5), followed by hypoparathyroidism (ages 3–10), and adrenal insufficiency later (ages 5–15). Over 95% of cases harbor one of two common AIRE mutations: R257X or an 13-bp deletion in exon 8.
What causes autoimmune polyglandular syndrome type 1?
APS-1 results from biallelic pathogenic variants in the AIRE gene, which encodes a transcription factor essential for thymic expression of peripheral tissue antigens. Over 60 mutations have been identified, leading to impaired negative selection of autoreactive T lymphocytes and failure of regulatory T cell development. This causes escape of self-reactive T cells into the periphery, triggering organ-specific autoimmunity.
Key pathophysiological mechanisms include:
- Autoantibodies against endocrine tissues (e.g., 21-hydroxylase in Addison disease, parathyroid calcium-sensing receptor in hypoparathyroidism).
- Defective IL-17-mediated antifungal immunity explaining chronic candidiasis.
- Interferon signature with neutralizing autoantibodies against type I interferons.
Inheritance is autosomal recessive; carriers are asymptomatic. Genetic testing confirms diagnosis by identifying AIRE mutations.
What are the clinical features of autoimmune polyglandular syndrome type 1?
The clinical course is variable but progressive, with components appearing in predictable sequence. Major manifestations occur in >50% of patients:
| Component | Frequency | Typical Age of Onset | Key Features |
|---|---|---|---|
| Chronic mucocutaneous candidiasis | 76–100% | <5 years | Oral/thrush, nail dystrophy, angular cheilitis |
| Hypoparathyroidism | 82–89% | 3–10 years | Tetany, seizures, basal ganglia calcification |
| Addison disease | 66–89% | 5–15 years | Fatigue, hyperpigmentation, salt craving |
| Gonadal failure | Females: 60%; Males: 15% | Puberty/adolescence | Amenorrhea, infertility |
| Autoimmune hepatitis | 10–20% | Variable | May progress to cirrhosis |
Minor/less common features (<20%):
- Intestinal: Malabsorption, autoimmune enteropathy, pernicious anaemia.
- Neurological: Encephalitis, peripheral neuropathy.
- Dermatological:
Vitiligo (20%), alopecia universalis (20%).
- Ocular: Keratoconjunctivitis, uveitis.
- Dental: Enamel hypoplasia.
- Other: Asplenia (10–20%), type 1 diabetes (5–15%), hypothyroidism.
Diagnosis
Definitive diagnosis requires:
- Two of the classic triad (CMC + hypoparathyroidism + Addison disease), OR
- One triad component + affected sibling, OR
- Pathogenic AIRE mutation.
Probable diagnosis: One triad feature before age 30 + associated condition (e.g., vitiligo, hepatitis) or specific autoantibodies (anti-interferon-ω/α, anti-NALP5).
Investigations
- Serum calcium, phosphate, PTH (low in hypoparathyroidism).
- ACTH stimulation test, 21-hydroxylase antibodies (Addison).
- AIRE gene sequencing.
- Autoantibody panel: 21OH, NAC, aromatic L-amino acid decarboxylase.
- Screen for asplenia (peripheral smear for Howell-Jolly bodies, abdominal imaging).
Treatment of autoimmune polyglandular syndrome type 1
Treatment is symptomatic and lifelong, targeting each autoimmune component:
- Hypoparathyroidism: Calcium + active vitamin D (calcitriol); recombinant PTH if refractory.
- Addison disease: Hydrocortisone + fludrocortisone; stress dosing for illness/surgery.
- Candidiasis: Topical (nystatin, azoles) + systemic fluconazole for refractory disease. Prophylaxis often needed.
- Gonadal failure: Hormone replacement (estrogen/progesterone in females).
- Hepatitis: Immunosuppressants (azathioprine, cyclosporine); liver transplant in end-stage.
- Asplenia: Vaccinations (pneumococcal, meningococcal, Hib), prophylactic penicillin.
Regular multidisciplinary surveillance is essential to detect new components early.
What is the outcome for autoimmune polyglandular syndrome type 1?
With hormone replacement and vigilant monitoring, life expectancy approaches normal. However, mortality risk (up to 5x higher) stems from adrenal crisis, hepatitis/cirrhosis, and infections. Addison crisis is the leading cause of death in undiagnosed/undertreated cases. Quality of life is impacted by polypharmacy and lifelong surveillance.
Related topics
- Autoimmune polyglandular syndrome type 2
- Addison disease
- Hypoparathyroidism
- Chronic mucocutaneous candidiasis
- Vitiligo
- Alopecia areata
Frequently asked questions about autoimmune polyglandular syndrome type 1
What is the first sign of APS-1?
Chronic mucocutaneous candidiasis, particularly oral thrush, is usually the earliest manifestation, appearing before age 5 years.
How is APS-1 diagnosed?
Diagnosis relies on clinical triad features, autoantibody testing, and confirmatory AIRE genetic sequencing.
Is APS-1 curable?
No, it is a lifelong genetic disorder managed with hormone replacement and symptomatic treatments.
Can APS-1 be fatal?
Yes, primarily from untreated adrenal crisis or autoimmune hepatitis progression.
Does APS-1 affect fertility?
Yes, ovarian failure causes infertility in most affected females; males less commonly affected.
References
- Autoimmune Polyglandular Syndrome Type 1 – Symptoms, Causes … — National Organization for Rare Disorders (NORD). 2023. https://rarediseases.org/rare-diseases/autoimmune-polyglandular-syndrome-type-1/
- Polyglandular Autoimmune Syndrome Type I – StatPearls — NCBI Bookshelf / StatPearls Publishing. 2023-10-01. https://www.ncbi.nlm.nih.gov/books/NBK537211/
- Autoimmune Polyglandular Syndrome Type 1 — PMC / National Institutes of Health. 2012-11-29. https://pmc.ncbi.nlm.nih.gov/articles/PMC3515937/
- Polyglandular Deficiency Syndromes — Merck Manual Professional Edition. 2024. https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/polyglandular-deficiency-syndromes/polyglandular-deficiency-syndromes
- APECED/APS-1 — Immune Deficiency Foundation. 2023. https://primaryimmune.org/understanding-primary-immunodeficiency/types-of-pi/apecedaps-1
Similar Articles
Read full bio of medha deb
